BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif. - December.
Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in. | November 10, 2022
/PRNewswire/ Trial Library, Inc., an oncology clinical trials company, today announced it has come out of stealth mode and received its first funding to.
Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track - Formal Notification Received of Sebetralstat EU Orphan Drug Status - KalVista Pharmaceuticals, Inc.